KB-1390

Bimagrumab

45614

Background of Bimagrumab

Bimagrumab-(BYM338)-is-a-fully-human-monoclonal-antibody-developed-by-Novartis,-primarily-targeting-the-activin-receptor-type-2B-(ActRIIB).-This-antibody-is-designed-to-treat-conditions-associated-with-muscle-loss-and-weakness,-such-as-sarcopenia-and-obesity-related-metabolic-disorders.-By-inhibiting-the-binding-of-natural-ligands-to-ActRIIB,-bimagrumab-promotes-muscle-hypertrophy-and-reduces-fat-mass,-making-it-a-potential-therapeutic-option-for-various-muscle-wasting-conditions.

Specifications

Catalog Number	KB-1390
Antibody Name	Bimagrumab
Isotype	Human IgG1,lambda
FC Muations	K214R/L234A/L235A/D356E/L358M
Target	ACVR2B
Species Reactivity	Human
Host Cell Line	EXPI CHO
Purification Method	Affinity purified
Concentration	>2 mg/mL
Formulation	50 mM sodium citrate,150mM NaCl,pH5.5
Purity	>95% by SDS-PAGE and SEC-HPLC
Validation	ELISA
Endotoxin Level	<0.2 EU/mg as determined by the LAL method
Sterility	0.2μm filtered
Storage	It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability	Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

Johanna-M,Laura-V,Teemu-K,et.al.Systemic-Blockade-of-ACVR2B-Ligands-Protects-Myocardium-from-Acute-Ischemia-Reperfusion-Injury.Mol-Ther-2019;27(3):600-610.
Oddrun-Elise-Olsen,Karin-Fahl-Wader,Hanne-Hella,et.al.Activin-A-inhibits-BMP-signaling-by-binding-ACVR2A-and-ACVR2B.Cell-Commun-Signal-2015;13(27).
Julia-S,Zoltan-Szabo,Juliana-Peter,et.al.Inhibition-of-activin-receptor-2-signalling-ameliorates-metabolic-dysfunction–associated-steatotic-liver-disease-in-western-diet/L-NAME-induced-cardiometabolic-disease.Biomedicine&Pharmacotherapy-2024;175.